Last reviewed · How we verify
Ibuvix® - ibuprofen
Inhibits COX-2 enzyme
Inhibits COX-2 enzyme Used for Pain management, Inflammation, Fever.
At a glance
| Generic name | Ibuvix® - ibuprofen |
|---|---|
| Sponsor | Apsen Farmaceutica S.A. |
| Drug class | NSAID |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the enzyme cyclooxygenase-2 (COX-2), which is involved in the production of prostaglandins, leading to pain, inflammation, and fever.
Approved indications
- Pain management
- Inflammation
- Fever
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibuvix® - ibuprofen CI brief — competitive landscape report
- Ibuvix® - ibuprofen updates RSS · CI watch RSS
- Apsen Farmaceutica S.A. portfolio CI